Omeros (NASDAQ:OMER) Cut to “Sell” at StockNews.com

StockNews.com lowered shares of Omeros (NASDAQ:OMER) from a hold rating to a sell rating in a research report released on Wednesday.

OMER has been the topic of a number of other reports. Needham & Company LLC restated a “hold” rating on shares of Omeros in a research report on Friday, January 17th. Rodman & Renshaw initiated coverage on shares of Omeros in a report on Thursday, November 14th. They issued a “buy” rating and a $9.00 price target on the stock. RODMAN&RENSHAW raised shares of Omeros to a “strong-buy” rating in a report on Thursday, November 14th. D. Boral Capital reissued a “buy” rating and issued a $36.00 target price on shares of Omeros in a research note on Thursday, February 20th. Finally, Cantor Fitzgerald restated a “neutral” rating on shares of Omeros in a research note on Thursday, November 14th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $22.50.

Omeros Stock Up 4.8 %

OMER stock opened at $8.36 on Wednesday. The business’s 50-day simple moving average is $9.18 and its 200 day simple moving average is $7.00. The company has a market cap of $484.46 million, a PE ratio of -3.62 and a beta of 2.03. Omeros has a twelve month low of $2.61 and a twelve month high of $13.60.

Institutional Investors Weigh In On Omeros

Several institutional investors and hedge funds have recently made changes to their positions in OMER. Truvestments Capital LLC lifted its holdings in Omeros by 116.5% during the 4th quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 1,669 shares during the last quarter. Tower Research Capital LLC TRC raised its stake in shares of Omeros by 79.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company’s stock valued at $44,000 after acquiring an additional 1,972 shares during the last quarter. Quantbot Technologies LP acquired a new position in shares of Omeros in the 4th quarter worth approximately $46,000. BNP Paribas Financial Markets grew its position in Omeros by 130.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company’s stock worth $49,000 after acquiring an additional 7,016 shares during the last quarter. Finally, Picton Mahoney Asset Management grew its position in Omeros by 692.5% during the 4th quarter. Picton Mahoney Asset Management now owns 5,040 shares of the biopharmaceutical company’s stock worth $50,000 after acquiring an additional 4,404 shares during the last quarter. Institutional investors and hedge funds own 48.79% of the company’s stock.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.